Promising PhII oral RA data triggers $30M milestone for Incyte

Incyte says that a mid-stage study of its oral therapy for rheumatoid arthritis achieved positive top-line results at the midway point of an ongoing six-month study, triggering a $30 million milestone payment from Eli Lilly. The developer also revealed in its current quarterly statement that it will pocket a $3 million milestone from Pfizer for its CCR2 antagonist program. "We have achieved positive three-month Phase II results for INCB28050, our oral JAK1/JAK2 inhibitor, for rheumatoid...